Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leeman, M
Right arrow Articles by Naeije, R
Right arrow Search for Related Content
PubMed
Right arrow Articles by Leeman, M
Right arrow Articles by Naeije, R

Chest, Vol 91, 662-666, Copyright © 1987 by American College of Chest Physicians

ARTICLES

Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD

M Leeman, P Lejeune, C Melot and R Naeije

Hemodynamics, blood gas values, and lung mechanics were investigated in 19 patients with decompensated COPD before and 30 and 60 minutes after a slow (15 minute) intravenous administration of 3 mg/kg enoximone (MDL 17,043). In the first 11 patients who were spontaneously breathing, enoximone significantly decreased pulmonary arterial wedge pressure, right atrial pressure, mean systemic arterial pressure, and mean pulmonary arterial pressure. Cardiac output remained unchanged, while heart rate increased slightly. Lung resistance decreased and dynamic lung compliance increased. Blood gas values remained unchanged. Similar effects were observed in the next eight patients who were artificially ventilated, except for an increase in cardiac output. These results show that enoximone has bronchodilating and pulmonary vasodilating properties.


This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
M. A. Giembycz
Phosphodiesterase-4: Selective and Dual-Specificity Inhibitors for the Therapy of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2005; 2(4): 326 - 333.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
Y. Hashimoto, K. Hirota, H. Yoshioka, T. Kudo, H. Ishihara, and A. Matsuki
A Comparison of the Spasmolytic Effects of Olprinone and Aminophylline on Serotonin-Induced Pulmonary Hypertension and Bronchoconstriction With or Without {beta}-Blockade in Dogs
Anesth. Analg., December 1, 2000; 91(6): 1345 - 1350.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
E. Hashiba, K. Hirota, H. Yoshioka, Y. Hashimoto, T. Kudo, T. Sato, and A. Matsuki
Milrinone Attenuates Serotonin-Induced Pulmonary Hypertension and Bronchoconstriction in Dogs
Anesth. Analg., April 1, 2000; 90(4): 790 - 794.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. MYOU, M. FUJIMURA, Y. KAMIO, Y. ISHIURA, H. TACHIBANA, T. HIROSE, T. HASHIMOTO, and T. MATSUDA
Bronchodilator Effect of Inhaled Olprinone, a Phosphodiesterase 3 Inhibitor, in Asthmatic Patients
Am. J. Respir. Crit. Care Med., September 1, 1999; 160(3): 817 - 820.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. B. Dowling, M. Johnson, P. J. Cole, and R. Wilson
The Effect of Rolipram, a Type IV Phosphodiesterase Inhibitor, on Pseudomonas aeruginosa Infection of Respiratory Mucosa
J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1565 - 1571.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. J. TORPHY
Phosphodiesterase Isozymes . Molecular Targets for Novel Antiasthma Agents
Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 351 - 370.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American College of Chest Physicians.